Key result
Nightly melatonin improves sleep, depression, anxiety, and quality of life versus placebo in hemodialysis patients.
Why the study?
Patients on hemodialysis frequently suffer from sleep and psychiatric disturbances, and the effects of exogenous oral melatonin on these symptoms and quality of life needed evaluation.
Does melatonin improve sleep disturbances, depression, anxiety, and quality of life in hemodialysis patients with sleep disorders?
RCT (n=60)
double-blind
randomized
Does melatonin improve sleep disturbances, depression, anxiety, and quality of life in hemodialysis patients with sleep disorders?
p-value: p=≤0.001
Melatonin 3 mg daily for three months safely improves sleep disturbances, depression, anxiety, and quality of life in hemodialysis patients.
Melatonin may improve sleep, depression, anxiety, and QoL in HD patients; leaves open need for larger confirmatory trials.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted an RCT in hemodialysis patients with sleep disorders (n=60). melatonin vs. placebo was evaluated on Sleep disturbances (PSQI, ISI), depression (HDRS), anxiety (HARS), and quality of life (QLI) (p=≤0.001). Melatonin 3 mg nightly significantly improved sleep disturbances (P≤0.001), depression (P≤0.001), anxiety (P=0.001), and quality of life (P=0.002) compared to placebo in hemodialysis patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: